This review found that leflunomide, methotrexate, and sulfasalazine did not differ in their effectiveness for treating rheumatoid arthritis, but leflunomide was more effective than placebo. These conclusions omitted the adverse effect findings and might not be reliable, due to the small number of trials for some comparisons, failure to specify a primary outcome, and high heterogeneity in many analyses.
Most participants in the included trials were women (66% to 88%). The mean participant age was over 50 years; the mean duration of rheumatoid arthritis was three to nine years; and over 60% of participants had the rheumatoid factor in their blood. Trials were conducted in various countries or groups of countries; all included between two and 117 centres. Leflunomide was given at a loading dose of 50 to 100mg and then usually at 20mg orally per day. It was compared with methotrexate (target dose 15mg per week), sulfasalazine (target dose 2g daily), or placebo.
Two reviewers independently selected studies for inclusion, with a third reviewer for arbitration if necessary.
Assessment of study quality
Trial quality was evaluated using the Jadad scale to assess the adequacy of reported randomisation, double-blinding, and withdrawals or dropouts. Each trial was awarded a score out of a maximum of five points. The sample size, number of participating centres, and duration of follow-up were also assessed.
The authors did not state how many reviewers assessed validity.
Data extraction
Mean differences were calculated for continuous data and relative risks for dichotomous (two options) data, both with 95% confidence intervals. In one study, with three intervention groups receiving different doses of leflunomide, only the 10mg group was included.
Two reviewers independently extracted the data, with a third reviewer for arbitration if necessary.
Methods of synthesis
The data were combined using a fixed-effect meta-analysis to calculate pooled risk ratios and weighted mean differences with 95% confidence intervals. Heterogeneity was assessed using Χ² and Ι². A random-effects model was used if heterogeneity was detected (Χ² p<0.1) or high (Ι²>50%).
